Carbohydrates (monosaccharides, oligosaccharides and polysaccharides) exist naturally in free from and as components of other macromolecules (nucleic acids, proteins and lipids). Glycotherapy refers to this use of carbohydrates or glycoengineered macromolecules in fighting life-threatening diseases. Although glycotherapy is a relatively new and limited field of pharmacology, significant progress has been made in recent years in academia and the pharmaceutical industry facilitated by advances in enzymology and recombinant DNA technologies. Consequently, carbohydrate containing biologics are now used in therapeutic regimens. This volume provides a summary of the progress made in developing therapeutic solutions using glycoengineering techniques. Topics covered in this volume include the development of vaccines and antibodies against tumor-associated carbohydrate antigens for cancer treatment, the use of glycan for viral inhibition, glycoPEGylation, hyaluronic acid conjugation, and protein modification and conjugation for increasing therapeutic index using recombinant and chemoenzymatic approaches. The volume is essential reading for biochemists, pharmacologists and R&D professionals interested in glycotherapy.

This new volume, Nanocarriers for Brain Targeting: Principles and Applications, covers recent research on brain physiology and the development of drug delivery systems. It explores a diverse variety of strategies that can be employed to achieve drug targeting to the brain. The nanocarriers that are discussed include nanoparticles, vesicular carriers, carriers having carbon as a core constituent, dispersed systems, and more. The inherent anatomy and physiology of the brain renders it different from other organs. The past few decades have witnessed significant research on brain ailments in response to a majority of hospitalizations that occur due to age-related central nervous system disorders. The prevalence of diverse diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV-dementia, etc., affect about 1.5 billion people globally, which is further anticipated to reach 1.9 billion by the year 2020. Nanocarriers for drug delivery to the brain are seen as one of the answers to this growing problem.

Advances in Carbohydrate Chemistry and Biochemistry has provided, since its inception in 1945, critical and informative articles written by research specialists that integrate the industrial, analytical, and technological aspects of biochemistry, organic chemistry, and instrumentation methodology to the study of carbohydrates. Its articles present a definitive interpretation of the current status and future trends in carbohydrate chemistry and biochemistry. - Features contributions from leading authorities and industry experts who specialize in carbohydrate chemistry, biochemistry, and research - Integrates the industrial, analytical, and technological aspects of biochemistry, organic chemistry, and instrumentation methodology in the study of carbohydrates - Informs and updates on all the latest developments in the field

Advances in Organic Synthesis is a book series devoted to the latest advances in synthetic approaches towards challenging structures. The series presents comprehensive reviews written by eminent authorities on different synthetic approaches to selected target molecules and new methods developed to achieve specific synthetic transformations or optimal product yields. Advances in Organic Synthesis is essential for all organic chemists in academia and the industry who wish to keep abreast of rapid and important developments in the field.

A new focus on glycoscience, a field that explores the structures and functions of sugars, promises great advances in areas as diverse as medicine, energy generation, and materials science, this report finds. Glycans-also known as carbohydrates, saccharides, or simply as sugars-play central roles in many biological processes and have properties useful in an array of applications. However, glycans have received little attention from the research community due to a lack of tools to probe their often complex structures and properties. Transforming Glycoscience: A Roadmap for the Future presents a roadmap for transforming glycoscience from a field dominated by specialists to a widely studied and integrated discipline, which could lead to a more complete understanding of glycans and help solve key challenges in diverse fields.

This book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms. It also includes discussion of new areas such as biotechnology and nanoparticles. Chapters explain the challenges and developments in anti-cancer drug discovery approaches, traditional remedies for prevention and treatment of cancer, marine-derived anti-cancer compounds, and antibiotics used as anti-cancer agents, as well as different classes of terpenoids and carbohydrates, which have been the subject of discussion in this field as efficient anti-cancer candidates. This book will be a concise guide for researchers in the field of pharmaceutical sciences, students and residents in pharmacy and medicine as well as those researching phytochemistry and natural products.

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases—30 Years Clinical Applications in China, and more. - Includes comprehensive coverage of molecular biology - Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided - Contains contributions from renowned experts in the field

Marine glycobiology is an emerging and exciting area in the field of science and medicine. Glycobiology, the study of the structure and function of carbohydrates and carbohydrate-containing molecules, is fundamental to all biological systems and represents a developing field of science that has made huge advances in the last half-century. This book revolutionizes the concept of marine glycobiology, focusing on the latest principles and applications of marine glycobiology and their relationships.

"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings’s College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.